Stoke Therapeutics (NASDAQ:STOK) Insider Arthur Tzianabos Sells 4,355 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Arthur Tzianabos sold 4,355 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the transaction, the insider directly owned 31,339 shares in the company, valued at $1,253,560. This trade represents a 12.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Stoke Therapeutics Stock Performance

Shares of STOK traded down $1.46 during trading hours on Thursday, reaching $36.48. 526,077 shares of the company traded hands, compared to its average volume of 733,735. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $40.22. The stock has a market cap of $2.08 billion, a P/E ratio of 54.45 and a beta of 1.07. The stock’s fifty day moving average is $32.57 and its 200 day moving average is $29.41.

Analysts Set New Price Targets

STOK has been the subject of several recent research reports. Chardan Capital increased their price target on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. HC Wainwright lifted their price target on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. UBS Group set a $50.00 price objective on Stoke Therapeutics in a report on Monday, December 15th. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, Loop Capital set a $35.00 price objective on Stoke Therapeutics in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics has an average rating of “Moderate Buy” and an average price target of $39.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics during the 4th quarter worth approximately $26,000. Harbour Investments Inc. increased its stake in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics in the third quarter valued at approximately $41,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after acquiring an additional 658 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.